1. Legally Approved Institutions for Stem Cell Therapy in China
As of April 2025, China has made significant strides in regulating stem cell therapies, particularly for knee osteoarthritis (KOA). Currently, the following institutions are recognized for their legal and compliant stem cell treatments:
- Divine Bay Hospital (Hainan Boao Lecheng International Medical Tourism Pilot Zone): Partnering with Aisair Biotech, Divine Bay Hospital pioneered the first legally approved clinical application of umbilical cord-derived mesenchymal stem cells (UC-MSCs) for KOA. Their project, co-developed with Ruijin Hospital Hainan Branch, passed rigorous regulatory reviews (3% approval rate) and emphasizes standardized clinical protocols and long-term efficacy monitoring.
- Shanghai Xibiman Biotech’s Collaborating Hospitals: Institutions like Renji Hospital and Shanghai Ninth People’s Hospital have conducted clinical trials for Xibiman’s AlloJoin, an off-the-shelf adipose-derived MSC product. This therapy, approved under NMPA’s 60-day Implied License system, focuses on scalability and safety in treating cartilage degeneration.
These institutions stand out for their adherence to China’s dual-filing system for clinical research, ensuring compliance with the Stem Cell Clinical Research Management Measures.
2. Why Stem Cell Therapy for KOA Is Legal: Regulatory Evidence
Stem cell therapies in China operate within a strict regulatory framework. Key legal validations include:
- National Medical Products Administration (NMPA) Approvals: Products like AlloJoin have received clinical trial permissions under the 2017 Technical Guidelines for Cell Therapy Product Evaluation, marking them as investigational new drugs (INDs).
- Institutional Compliance: Legitimate treatments are confined to Grade III-A hospitals with ethical review boards and GMP-certified facilities. For example, Divine Bay Hospital’s project underwent multi-layered ethical and technical evaluations.
- Policy Support: The 2024 Chinese Osteoarthritis Diagnosis and Treatment Guidelines explicitly endorse MSC intra-articular injections as a repair-oriented therapy for early-stage KOA, aligning with national efforts to promote regenerative medicine.
Illegal practices, such as unapproved “stem cell clinics” highlighted in court cases, contrast sharply with these regulated programs, underscoring the importance of choosing compliant providers.
3. Advantages Over Traditional Treatments
Stem cell therapy addresses critical limitations of conventional KOA management:
| Traditional Methods | Stem Cell Therapy |
|---|---|
| Drugs (NSAIDs, steroids): Temporarily relieve pain but fail to regenerate cartilage. Long-term use risks gastrointestinal/cardiovascular harm. Surgery (e.g., joint replacement): Invasive, costly, and prone to complications (e.g., infections, limited implant durability). | Cartilage Regeneration: UC-MSCs differentiate into chondrocytes and secrete anti-inflammatory factors (e.g., TGF-β, IL-10), restoring joint structure. Sustained Efficacy: Clinical trials show pain reduction (WOMAC scores ↓2.66x vs. 1.01x in steroid groups) and functional improvement persisting for ≥1 year. Minimally Invasive: Intra-articular injections avoid surgical risks, with 80% of patients reporting only transient joint pain. |
Notably, MSC therapies modulate the inflammatory microenvironment rather than merely masking symptoms, offering a paradigm shift toward “functional cure”.
4. Challenges and Future Directions
Despite progress, challenges remain:
- Cost and Accessibility: Treatments like double-knee MSC injections cost ~¥80,000, currently excluded from insurance.
- Standardization: Variability in cell dosage, preparation, and patient selection necessitates multi-center trials for protocol optimization.
Emerging innovations—such as 3D-printed cartilage scaffolds and exosome-based therapies—may further enhance efficacy and affordability.
As a researcher passionate about regenerative medicine, I believe stem cell therapy represents a transformative frontier for KOA. However, patients must verify institutional compliance with national regulations to ensure safety and efficacy.
English
Chinese
French
Spanish